First-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs),
gefitinib and erlotinib, produce reliable responses and survival benefits in selected patients …

The epidermal growth factor receptor (EGFR) has been widely used as a target for novel
anticancer agents, such as blocking antibodies and small molecular weight tyrosine kinase …

The widespread adoption of epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors for the first‐line treatment of patients with advanced EGFR‐mutated non‐small cell …

Lung cancer represents the leading cause of cancer-related deaths worldwide. Despite
great advances in its management with the recent emergence of molecular targeted …

EGFR is a member of the ERBB family. It plays a significant role in cellular processes such
as growth, survival and differentiation via the activation of various signaling pathways. EGFR …

Irreversible pyrimidine-based EGFR inhibitors, including WZ4002, selectively inhibit both
EGFR-activating and EGFR inhibitor–resistant T790M mutations more potently than wild …

Cancer therapies targeting epidermal growth factor receptor (EGFR), such as small-
molecule kinase inhibitors and monoclonal antibodies, have been developed as standard …

In the last 5 years the epidermal growth factor receptor (EGFR) has emerged as one of the
most important targets for drug development in oncology. Monoclonal antibodies targeting …

Non-Small-Cell Lung Cancer (NSCLC) with somatic mutations of the epidermal growth
factor receptor (EGFR) is anticipated to respond to small-molecule tyrosine kinase inhibitors …

Background Epidermal growth factor receptor (EGFR) signaling plays an important role in
non-small cell lung cancer (NSCLC) and therapeutics targeted against EGFR have been …